23 September 2020
Our presenters, Stephen Garner and Anna Gregson, discuss how EPO case law has developed since revocation of the dasatinib patent in 2017, and explore how innovators should adjust their filing and drafting strategy in light of the EPO’s post-dasatinib approach to plausibility.
Sign up to our mailing list to receive Mathys Matters, our monthly newsletter covering the latest IP news, industry insights, events and case law.
If you are interested in receiving quarterly newsletters relevant to our core sector groups - IT & engineering ('Inside Wires') and life sciences & chemistry ('Under the Microscope') - please select your preference(s) below:
Please select your practice area(s) of interest: